Vestal Point Capital LP Acquires Shares of 525,000 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Vestal Point Capital LP acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 525,000 shares of the company's stock, valued at approximately $6,122,000. Vestal Point Capital LP owned approximately 0.52% of Intellia Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ensign Peak Advisors Inc boosted its holdings in shares of Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock valued at $457,000 after purchasing an additional 1,100 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Intellia Therapeutics by 14.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock valued at $157,000 after acquiring an additional 1,582 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Intellia Therapeutics by 6.1% during the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock valued at $327,000 after acquiring an additional 1,615 shares in the last quarter. E Fund Management Co. Ltd. lifted its holdings in Intellia Therapeutics by 10.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock worth $210,000 after buying an additional 1,634 shares in the last quarter. Finally, Virtus ETF Advisers LLC lifted its holdings in Intellia Therapeutics by 47.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock worth $61,000 after buying an additional 1,692 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NTLA. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price objective on the stock in a report on Monday, April 21st. Barclays lowered their price objective on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. The Goldman Sachs Group restated a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Citigroup decreased their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, Wells Fargo & Company decreased their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Intellia Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $36.90.

Intellia Therapeutics Stock Performance

Shares of NASDAQ:NTLA traded down $0.47 during mid-day trading on Wednesday, hitting $9.20. The stock had a trading volume of 4,182,130 shares, compared to its average volume of 2,552,578. The company has a market cap of $952.96 million, a PE ratio of -1.69 and a beta of 2.33. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.18. The company's 50 day moving average is $7.99 and its 200-day moving average is $10.67.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analysts' expectations of $11.39 million. The firm's revenue was down 42.6% compared to the same quarter last year. During the same quarter last year, the company posted ($1.12) EPS. On average, equities research analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.